LEQVIO (generic name: inclisiran) is a prescription medication used to manage cholesterol levels in adults. Specifically, it is designed for individuals who have been diagnosed with cardiovascular disease or those who have an inherited condition leading to high levels of LDL cholesterol, often referred to as "bad" cholesterol, despite taking the maximum tolerated dose of statin therapy. LEQVIO belongs to a class of drugs known as small interfering RNA (siRNA) therapeutics. It works by targeting and silencing specific RNA molecules involved in the production of PCSK9, a protein that reduces the liver's ability to remove LDL cholesterol from the blood. By inhibiting PCSK9, LEQVIO effectively lowers LDL cholesterol levels, thereby reducing the risk of cardiovascular events such as heart attacks and strokes. This medication is administered through subcutaneous injection and is noted for its dosing schedule, which after the initial doses, requires maintenance doses typically twice a year.